Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | KMO | O15229 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3483616 | 0.88 | CYP1A2 (0.45) | CYP1A2RECQLKMOPOLBHSD17B10 | |
| SCHEMBL188240 | 0.86 | CYP1A2 (0.39) | CYP1A2RECQLKMOCYP11B2HASPIN | |
| SCHEMBL17610869 | 0.85 | CYP1A2 (0.43) | CYP1A2RECQLKMOPOLBHSD17B10 | |
| SCHEMBL16617269 | 0.83 | CYP1A2 (0.41) | CYP1A2RECQLKMOPOLBHSD17B10 | |
| SCHEMBL16617402 | 0.82 | CYP1A2 (0.42) | CYP1A2RECQLKMOPOLBHSD17B10 | |
| SCHEMBL27243721 | 0.81 | CYP1A2 (0.45) | CYP1A2RECQLKMODAOHTR2A | |
| SCHEMBL3482763 | 0.81 | CYP1A2 (0.45) | CYP1A2RECQLKMODAOHTR2A | |
| SCHEMBL6750648 | 0.80 | CYP1A2 (0.42) | CYP1A2RECQLKMOHTR2AHTR2C | |
| SCHEMBL3192376 | 0.80 | CYP1A2 (0.42) | CYP1A2RECQLKMODAOHTR2A | |
| SCHEMBL3187768 | 0.80 | MAOB (0.44) | CYP1A2RECQLKMOHSD17B10HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107074822-B | Triazole compounds as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | claimed |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-04-02 | — | — | US | claimed |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-18 | — | — | US | claimed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | claimed |
| EP-2912037-B1 | 2-AMINOPYRIDINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-08-22 | — | — | EP | claimed |
| EP-3194374-B1 | TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-08-01 | — | — | EP | claimed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | claimed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | claimed |
| US-9834541-B2 | 2-aminopyridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-12-05 | — | — | US | claimed |
| US-20150353548-A1 | 2-AMINOPYRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-12-10 | — | — | US | claimed |
| EP-2912037-A1 | 2-AMINOPYRIDINE COMPOUNDS | Merck Patent GmbH (DE) | 2015-09-02 | — | — | EP | claimed |
| EP-2892892-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2015-07-15 | — | — | EP | claimed |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA, NV (BE) | 2015-04-09 | — | — | US | claimed |
| WO-2014063778-A1 | 2-AMINOPYRIDINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2014-05-01 | — | — | WO | claimed |
| WO-2014039769-A1 | IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-13 | — | — | WO | claimed |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-02-25 | — | — | US | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | CYP1A2 507/4885RECQL 1119/4885KMO 1448/4885 |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | CYP1A2 612/4885RECQL 3885/4885KMO 425/4885 |
| US-10246426-B2 | Triazole compounds as T-type calcium channel blockers | CACNA1I, CACNA1E, CACNA1G | CYP1A2 581/4885RECQL 906/4885KMO 1537/4885 |
| US-20150099730-A1 | IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER | FASN, PLIN1, FABP1 | CYP1A2 439/4885RECQL 695/4885KMO 2451/4885 |
| US-10077261-B2 | Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer | FASN, PLIN1, FABP1 | CYP1A2 439/4885RECQL 695/4885KMO 2451/4885 |
| US-20150353548-A1 | 2-AMINOPYRIDINE COMPOUNDS | SKP2, CDKN1A, MKI67 | CYP1A2 710/4885RECQL 2074/4885KMO 351/4885 |
| US-20100048893-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | CYP1A2 486/4885RECQL 3770/4885KMO 342/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | CYP1A2 507/4885RECQL 1119/4885KMO 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.